AcquisitionOther
SUPERNUS PHARMACEUTICALS, INC. acquired target
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
SUPERNUS PHARMACEUTICALS, INC. -> target · $125 million
Commission File No.: 001-35518 Date: August 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale · Combines highly complementary businesses, with a diversified
Open source record (SEC) ↗